| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
BeOne Medicines Ltd.$317.42
+6.16 (+1.98%)
A 85Pipeline Score Undervalued Pharma · Commercial
Market Cap
35.06 B
EPS
4.67
P/E Ratio
69.23 $
Value Trade
57.42 M
SEC Financials
Q1 2026Dilution Risk
Revenue
1.51 B
R&D Expenses
541.22 M
Operating CF
201.34 M
Total Assets
8.55 B
Total Liabilities
3.79 B
Equity
4.76 B
D/E Ratio
12,345
3.42 %
Week
-0.83 %
1 Month
-12.84 %
3 Month
-11.15 %
6 Month
-9.94 %
5 Year
970.94 %
All Time
Cash Data
Cash Position
4.79 B
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 6, 2026
Overview
Volume
594.85 K
52 Week Range
235.35 - 385.22
% held by Insiders
0.52 %
% held by Institutions
33.69 %
Enterprise Value
32.28 B
Total Shares
102.30 M
Short %
0.78 %
Float Shares
101.77 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for BeOne Medicines Ltd.
785Total events
16Upcoming
382Tier-1 (high impact)
2018 – 2026Coverage
Upcoming catalysts 2
TBD
T2Oral Presentation
Subscribe to view catalyst details
TBD
T2Other Regulator Milestone
Subscribe to view catalyst details
Event history 2
TBD
▲Primary Endpoint MetBRUKINSAApprovedClinical Data
Subscribe to view catalyst details
TBD
◆Other Regulator MilestoneTEVIMBRAApprovedEx-US Regulatory
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-05-13 | Beqalzi (sonrotoclax) | PDUFA Date | PDUFA | Approved | – | – | – |
2026-05-13 | Beqalzi (sonrotoclax) | PDUFA Date | PDUFA | Approved | – | – | – |
2026-05-13 | Beqalzi (sonrotoclax) | PDUFA Date | PDUFA | Approved | – | – | – |
Drug Pipeline Intelligence
A85
Pipeline Score $38.5B
Pipeline ValueUndervalued
Valuation Signal55
Drugs Scored3.4x
rNPV / MCap Top 98%
Mid Cap (rank 19 of 912)
Percentile RankBeOne Medicines Ltd. earns an A-grade pipeline score (85/100), with $45.3B risk-adjusted pipeline value, led by lenvatinib in Advanced Solid Tumor (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lenvatinib Small molecule | Hepatocellular Carcinoma | Phase 2 | NCT04401800 | 19% | $8.7B | COMPLETED | 64 | - | - | Feb 18, 2024 | - | Mar 10, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
BRUKINSA | LLC | — | 2026-06-01 | 78 months | BeOne Medicines établit une nouvelle référence en matière de contrôle à long terme de la LLC grâce aux données sur 78 mois concernant BRUKINSA présentées lors de l’ASCO 2026 Read More | |
BRUKINSA | LLC | — | 2026-06-01 | 78 months | BeOne Medicines établit une nouvelle référence en matière de contrôle à long terme de la LLC grâce aux données sur 78 mois concernant BRUKINSA présentées lors de l’ASCO 2026 Read More | |
BRUKINSA | LLC | — | 2026-06-01 | 78 months | BeOne Medicines établit une nouvelle référence en matière de contrôle à long terme de la LLC grâce aux données sur 78 mois concernant BRUKINSA présentées lors de l’ASCO 2026 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ONC
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ONC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ONCBeOne Medicines anuncia resultados positivos da Fase 3 para o BRUKINSA no tratamento de primeira linha do linfoma de células do manto
BeOne Medicines has announced positive results from a Phase 3 trial for BRUKINSA, which is being evaluated as a first-line treatment for mantle cell lymphoma. The study indicates that BRUKINSA may enhance patient outcomes significantly. This development marks a crucial step forward in the treatment landscape for this type of lymphoma.
Read more →ONCBeOne Medicines anuncia resultados positivos de fase 3 para BRUKINSA en el tratamiento de primera línea del linfoma de células del manto
BeOne Medicines has announced positive results from a Phase 3 trial for BRUKINSA, which is being evaluated as a first-line treatment for mantle cell lymphoma. The results indicate that BRUKINSA may provide significant benefits for patients, potentially improving treatment outcomes. This development marks a crucial step in the advancement of therapies for this type of lymphoma.
Read more →ONCRiassunto: BeOne Medicines annuncia i risultati positivi di fase 3 per BRUKINSA, come trattamento di prima linea per il linfoma a cellule mantellari (MCL)
BeOne Medicines has reported positive results from a Phase 3 trial of BRUKINSA, indicating its effectiveness as a first-line treatment for mantle cell lymphoma (MCL). This development could significantly enhance treatment options for patients with MCL. The results are expected to impact future treatment protocols.
Read more →ONCSamenvatting: BeOne Medicines maakt positieve fase 3-resultaten bekend voor BRUKINSA bij eerstelijnsbehandeling van mantelcellymfoom
BeOne Medicines has announced positive Phase 3 results for BRUKINSA, indicating its effectiveness as a first-line treatment for mantle cell lymphoma. This development suggests a significant advancement in therapeutic options for patients. The results may enhance the drug's market position and patient outcomes.
Read more →ONCBeOne Medicines meldet positive Phase-3-Ergebnisse für BRUKINSA bei Erstlinientherapie des Mantelzell‑Lymphoms
BeOne Medicines has announced positive Phase 3 results for BRUKINSA in the treatment of mantle cell lymphoma. This first-line therapy demonstrates promising efficacy, potentially improving treatment options for patients. The results may lead to further advancements in the management of this condition.
Read more →ONCBeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma
BeOne Medicines has announced positive Phase 3 results for BRUKINSA, indicating its potential effectiveness as a frontline treatment for mantle cell lymphoma. This development could significantly impact treatment options for patients. The results are seen as a promising advancement in the field of oncology.
Read more →ONCLa division hématologique phare de BeOne Medicines ouvre la voie à une nouvelle ère d’innovation dans le traitement des cancers à cellules B lors du congrès EHA 2026
BeOne Medicines' hematology division is set to lead innovations in B-cell cancer treatments, as highlighted at the EHA 2026 congress. The announcement suggests a focus on advancing therapeutic options in this area. Further details on specific innovations or clinical data were not disclosed.
Read more →ONCDas grundlegende hämatologische Produktportfolio von BeOne Medicines läutet auf der EHA 2026 eine neue Ära der Innovation bei B-Zell-Krebserkrankungen ein
BeOne Medicines is set to unveil its innovative hematological product portfolio at EHA 2026, focusing on advancements in B-cell malignancies. This event marks a significant moment for the company as it aims to introduce new solutions in the treatment landscape. The presentation is anticipated to attract attention from industry stakeholders and researchers alike.
Read more →ONCLa línea de productos de hematología de BeOne Medicines marca el rumbo de la próxima era de innovación en el cáncer de células B en la EHA 2026
BeOne Medicines is positioning its hematology product line as a key player in the future of B-cell cancer innovation, as highlighted at EHA 2026. The company's focus on advancing treatments reflects ongoing developments in the field. Further details on specific innovations or product features were not provided in the article.
Read more →ONCBeOne präsentiert auf der EHA 2026 wegweisende Daten aus der Phase-3-Studie bei CLL-Patienten im Alter von über 80 Jahren und untermauert damit den Nutzen von BRUKINSA
BeOne presented data at EHA 2026 from a Phase 3 study focusing on CLL patients over 80 years old, highlighting the benefits of BRUKINSA. The presentation aimed to demonstrate the drug's efficacy and safety in this specific patient demographic. Further details on the study's outcomes were not provided.
Read more →ONCFranquia de hematologia fundamental da BeOne Medicines lidera próxima era da inovação em câncer de células B na EHA 2026
BeOne Medicines is poised to lead innovation in B-cell cancer treatment, as highlighted in their upcoming presentation at EHA 2026. The company focuses on hematology and aims to introduce groundbreaking therapies. Further details on specific innovations or data were not provided in the article.
Read more →ONCBeOne Medicines的基礎血液學產品線在EHA 2026上引領B細胞癌症創新新時代
BeOne Medicines is set to present its foundational blood product line at EHA 2026, focusing on innovative treatments for hematological malignancies. The event aims to showcase advancements in the field and highlight the company's contributions. Details about specific products or research findings were not disclosed in the article.
Read more →ONCRiassunto: Il franchising ematologico di base di BeOne Medicines guida la prossima era dell'innovazione oncologica delle cellule B all'EHA 2026
The article discusses BeOne Medicines' hematologic franchise and its role in advancing B-cell oncology innovation, particularly in the context of the upcoming EHA 2026 event. However, the content lacks specific details or developments regarding the franchise or innovations. Overall, it presents a neutral outlook on the company's initiatives.
Read more →ONCSamenvatting: De toonaangevende hematologie-divisie van BeOne Medicines luidt op EHA 2026 een nieuw tijdperk in voor innovatie op het gebied van B-celkanker
The article discusses BeOne Medicines' hematology division and its innovations in B-cell cancer, which will be highlighted at EHA 2026. However, specific details about these innovations or their implications are not provided.
Read more →ONCBeOne presenta en la EHA 2026 resultados históricos de fase 3 en pacientes de 80 años o más con LLC que confirman el beneficio de BRUKINSA
BeOne presented historical Phase 3 results at EHA 2026 regarding the benefits of BRUKINSA in patients aged 80 and older with CLL. The findings contribute to the understanding of treatment efficacy in this demographic. Further details on the study's outcomes were not provided in the article.
Read more →ONCBeOne在EHA 2026上展示具有里程碑意義的80歲以上CLL病患第三期資料，進一步證實BRUKINSA的獲益
The article discusses BeOne's presentation at EHA 2026, focusing on the implications of BRUKINSA for CLL patients aged 80 and above. However, the content lacks specific details about the findings or implications of the study.
Read more →ONCBeOne présente des données historiques de phase 3 chez des patients atteints de LLC âgés de 80 ans et plus lors du congrès EHA 2026, confirmant ainsi les bénéfices de BRUKINSA
BeOne presented historical Phase 3 data at the EHA 2026 congress, focusing on patients aged 80 and older with chronic lymphocytic leukemia (CLL). The data confirmed the benefits of BRUKINSA in this demographic. The presentation highlights the ongoing research and development efforts in treating CLL among elderly patients.
Read more →ONCBeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026
BeOne Medicines is highlighting its hematology franchise at EHA 2026, focusing on B-cell cancer innovation. The event aims to showcase advancements in treatment options and research. Details about specific innovations or data were not provided in the article.
Read more →ONCBeOne apresenta dados históricos da Fase 3 em pacientes com LLC com mais de 80 anos na EHA 2026, reforçando os benefícios do BRUKINSA
BeOne presented historical Phase 3 data on patients over 80 years old with CLL at EHA 2026, highlighting the benefits of BRUKINSA. The presentation focused on the efficacy and safety of the treatment in this specific age group, contributing to the ongoing discussion about treatment options for elderly patients with chronic lymphocytic leukemia.
Read more →ONCRiassunto: BeOne presenta dati fondamentali di Fase 3 di pazienti affetti da CLL di età superiore agli 80 anni in occasione di EHA 2026, ribadendo il vantaggio di BRUKINSA
BeOne presented Phase 3 data on patients over 80 years old with CLL at EHA 2026, emphasizing the benefits of BRUKINSA. The findings contribute to understanding treatment options for elderly patients with chronic lymphocytic leukemia. Further details about the study's outcomes and implications were not disclosed.
Read more →ONCSamenvatting: BeOne presenteert baanbrekende Fase 3-gegevens bij CLL-patiënten van 80 jaar en ouder op EHA 2026, waarmee het voordeel van BRUKINSA wordt bevestigd
The article discusses the presentation of groundbreaking Phase 3 data by BeOne regarding BRUKINSA in patients aged 80 and older with CLL at EHA 2026. The data confirms the benefits of BRUKINSA for this demographic. However, specific details about the findings or implications are not provided.
Read more →ONCBeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit
BeOne presented significant Phase 3 data regarding BRUKINSA for CLL patients aged 80 and older at EHA 2026. The findings aim to reinforce the benefits of BRUKINSA in this demographic. Further details on the data and its implications were not disclosed in the article.
Read more →ONCBeOne Medicines präsentiert auf der ASCO 2026 neue Daten zur Beschleunigung seiner Pipeline für solide Tumoren
BeOne Medicines presented new data at ASCO 2026 aimed at accelerating its pipeline for solid tumors. The presentation highlights the company's ongoing efforts to advance its therapeutic developments. Details on specific data or results were not provided in the article.
Read more →ONCBeOne Medicines在2026年ASCO年會上發表新資料，彰顯實質腫瘤研發產品線的加速發展
BeOne Medicines is set to present new data at the 2026 ASCO annual meeting. The focus will be on accelerating the development of their innovative cancer therapies. Further details on the specific products and findings are not provided in the article.
Read more →ONCBeOne Medicines met en avant l’accélération de son pipeline dédié aux tumeurs solides grâce à de nouvelles données présentées lors de l’ASCO 2026
BeOne Medicines highlighted the acceleration of its pipeline focused on solid tumors, with new data presented at ASCO 2026. The company aims to advance its therapeutic offerings in oncology. Further details on the specific data and implications for the pipeline were not provided.
Read more →ONCSamenvatting: BeOne Medicines belicht versnelling in de pijplijn voor vaste tumoren met nieuwe gegevens tijdens ASCO 2026
BeOne Medicines presented new data regarding the acceleration of their pipeline for solid tumors at ASCO 2026. The article highlights the company's focus on advancing their research and development efforts in this area. However, specific details about the findings or implications were not provided.
Read more →ONCRiassunto: BeOne Medicines evidenzia l'accelerazione della sua pipeline dedicata ai tumori solidi con la presentazione di nuovi dati ad ASCO 2026
BeOne Medicines has highlighted the acceleration of its pipeline focused on solid tumors, presenting new data at ASCO 2026. The details of the data and its implications for the company's future developments were not disclosed in the article. This presentation marks a significant event for BeOne as it continues to advance its research.
Read more →ONCA BeOne Medicines destaca o avanço acelerado de seu pipeline de tumores sólidos com novos dados na ASCO 2026
BeOne Medicines has made an announcement regarding the accelerated advancement of its solid tumor pipeline, presenting new data at ASCO 2026. However, the article lacks specific details about the findings or implications of this advancement.
Read more →ONCBeOne Medicines destaca los avances en su cartera de productos para tumores sólidos con nuevos datos presentados en ASCO 2026
BeOne Medicines has highlighted advancements in its solid tumor product portfolio at ASCO 2026. The presentation showcased new data, although specific details were not disclosed in the article. This event marks a significant moment for the company as it continues to develop its offerings in oncology.
Read more →ONCBeOne Medicines établit une nouvelle référence en matière de contrôle à long terme de la LLC grâce aux données sur 78 mois concernant BRUKINSA présentées lors de l’ASCO 2026
BeOne Medicines has established a new long-term control reference for LLC based on 78 months of data regarding BRUKINSA, presented at ASCO 2026. The findings contribute to the understanding of BRUKINSA's effectiveness over an extended period. Further details on the implications of this data remain limited.
Read more →ONCBeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 2026
BeOne Medicines presented new data regarding its solid tumor pipeline at ASCO 2026. The company aims to accelerate the development of its treatments for solid tumors. Specific details about the data and its implications were not disclosed in the article.
Read more →ONCBeOne Medicines在2026年ASCO年會上公布BRUKINSA的78個月資料，確立其在CLL長期疾病控制中的標準
BeOne Medicines is set to present data on BRUKINSA at the 2026 ASCO annual meeting. The focus will be on its efficacy in managing chronic lymphocytic leukemia (CLL). Further details on the data and its implications for treatment are anticipated.
Read more →ONCBeOne Medicines establece un nuevo estándar para el control a largo plazo de la leucemia linfocítica crónica (LLC) con los datos de 78 meses de BRUKINSA que se presentaron en ASCO 2026
BeOne Medicines has set a new standard for long-term management of chronic lymphocytic leukemia (CLL) with 78-month data on BRUKINSA presented at ASCO 2026. The findings suggest significant implications for treatment protocols in CLL. Further details on the data and its impact on clinical practices were not disclosed.
Read more →ONCBeOne Medicines setzt mit den 78-Monats-Daten zu BRUKINSA auf der ASCO 2026 neue Maßstäbe für die langfristige Krankheitskontrolle bei CLL
BeOne Medicines presented 78-month data on BRUKINSA at ASCO 2026, highlighting its potential for long-term disease control in chronic lymphocytic leukemia (CLL). This presentation sets new benchmarks in the management of CLL. The data may influence future treatment protocols and patient outcomes.
Read more →ONCSamenvatting: BeOne Medicines stelt norm voor langdurige ziektecontrole bij CLL met BRUKINSA-gegevens van 78 maanden op ASCO 2026
BeOne Medicines presented data on BRUKINSA at ASCO 2026, highlighting a standard for long-term disease control in chronic lymphocytic leukemia (CLL). The findings are based on 78 months of data, showcasing the potential of BRUKINSA in managing CLL effectively. This presentation marks a significant step in establishing treatment benchmarks for CLL.
Read more →ONCRiassunto: BeOne Medicines definisce uno standard per il controllo della malattia a lungo termine nella LLC con i dati a 78 mesi di BRUKINSA all'ASCO 2026
BeOne Medicines has established a long-term disease control standard in LLC using 78-month data from BRUKINSA presented at ASCO 2026. The findings contribute to the understanding of treatment efficacy over an extended period. Further details on the implications of these results were not provided.
Read more →ONCBeOne Medicines estabelece padrão para controle de longo prazo da doença em LLC com dados de 78 meses de BRUKINSA no ASCO 2026
BeOne Medicines has established a long-term disease control standard for LLC using data from a 78-month study of BRUKINSA, presented at ASCO 2026. The findings highlight the efficacy of BRUKINSA in managing LLC over an extended period. This research aims to improve treatment protocols and patient outcomes in LLC.
Read more →ONCBeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026
BeOne Medicines presented data on BRUKINSA at ASCO 2026, highlighting its potential for long-term disease control in chronic lymphocytic leukemia (CLL). The 78-month data suggests promising outcomes for patients. However, further details on the study's methodology and results were not disclosed in the article.
Read more →ONCBeOne Medicines annonce les données de l'essai HERIZON-GEA de phase 3 publiées dans le NEJM et présentées à l'ASCO 2026
BeOne Medicines announced the phase 3 HERIZON-GEA trial data published in NEJM and presented at ASCO 2026. The details of the trial and its implications for the treatment landscape were highlighted. This announcement marks a significant milestone for the company in its ongoing research efforts.
Read more →ONCBeOne Medicines gibt bekannt, dass die Phase-3-Daten der Studie HERIZON-GEA im NEJM veröffentlicht und auf der ASCO 2026 vorgestellt wurden
BeOne Medicines announced the publication of Phase 3 data from the HERIZON-GEA study in NEJM and its presentation at ASCO 2026. This highlights the company's ongoing research efforts and commitment to advancing cancer treatment. Further details regarding the study's findings were not disclosed in the announcement.
Read more →ONCSamenvatting: BeOne Medicines kondigt publicatie aan van Fase 3 HERIZON-GEA-gegevens in NEJM en presentatie ervan op ASCO 2026
BeOne Medicines has announced the publication of Phase 3 HERIZON-GEA data in NEJM and its presentation at ASCO 2026. This event marks a significant milestone for the company, showcasing their advancements in cancer treatment. Further details about the findings and implications for future research are anticipated.
Read more →ONCRiassunto: BeOne Medicines annuncia i dati di fase 3 HERIZON-GEA pubblicati in NEJM e presentati all'ASCO 2026
BeOne Medicines has announced the phase 3 HERIZON-GEA data, which have been published in NEJM and presented at ASCO 2026. The announcement highlights the company's ongoing research efforts and contributions to the field. Further details on the findings and implications were not provided in the article.
Read more →ONCBeOne Medicines anuncia dados da Fase 3 do estudo HERIZON-GEA publicados no NEJM e apresentados na ASCO 2026
BeOne Medicines has announced the publication of Phase 3 study data from HERIZON-GEA in the New England Journal of Medicine and its presentation at ASCO 2026. The details regarding the findings and implications of this study are currently not available.
Read more →ONCBeOne Medicines anuncia la publicación de los datos de fase 3 HERIZON-GEA en NEJM y su presentación en ASCO 2026
BeOne Medicines has announced the publication of phase 3 HERIZON-GEA data in NEJM and its upcoming presentation at ASCO 2026. This marks a significant milestone for the company as it shares important findings from its clinical trials. The details of the data and its implications for future treatments are yet to be fully disclosed.
Read more →ONCBeOne Medicines公布HERIZON-GEA第三期研究結果，刊登《NEJM》並於ASCO 2026發表
BeOne Medicines has announced the results of the HERIZON-GEA Phase 3 study, which will be published in NEJM and presented at ASCO 2026. The details of the study results and their implications for the company and the broader field are yet to be disclosed.
Read more →ONCBeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 2026
BeOne Medicines has announced that data from its Phase 3 HERIZON-GEA trial has been published in the New England Journal of Medicine and presented at the ASCO 2026 conference. This marks a significant milestone for the company as it shares important findings from its clinical research. Further details about the data and implications for treatment were not disclosed.
Read more →ONCBeOne Medicines to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
BeOne Medicines is scheduled to present at the Goldman Sachs 47th Annual Global Healthcare Conference. The article does not provide further details about the presentation or the company's agenda at the event.
Read more →ONCBeOne Medicines lidera el avance en oncología con más de 60 abstracts en la reunión anual de la ASCO y en el congreso de la EHA 2026
BeOne Medicines is leading advancements in oncology with over 60 abstracts presented at the annual ASCO meeting and the EHA congress in 2026. This significant participation highlights the company's commitment to oncology research and development. The details of the abstracts and their implications for the field were not disclosed in the article.
Read more →ONCBeOne Medicines gibt auf der ASCO und der EHA 2026 mit über 60 Abstracts das Tempo in der Onkologie vor
BeOne Medicines announced its participation in ASCO and EHA 2026, presenting over 60 abstracts. This highlights the company's active role in oncology research and development. The event is expected to showcase significant advancements in the field, although specific details about the abstracts were not provided.
Read more →ONCBeOne Medicines攜60餘篇摘要亮相2026年ASCO年會和EHA大會，引領腫瘤學領域尖端進展
BeOne Medicines has announced its participation in the upcoming ASCO and EHA conferences in 2026. The focus will be on advancements in the field of oncology, particularly in the treatment of blood cancers. Further details regarding their presentations and research findings are anticipated as the events approach.
Read more →ONCBeOne Medicines donne le ton en oncologie lors des congrès de l'ASCO et de l'EHA 2026 avec plus de 60 résumés
BeOne Medicines is set to make a significant impact in oncology at the upcoming ASCO and EHA 2026 congresses with over 60 abstracts. This participation highlights the company's commitment to advancing cancer treatment and research. The details of the abstracts and their implications for the field are yet to be disclosed.
Read more →ONCBeOne Medicines lidera o setor de oncologia na ASCO e na EHA 2026 com mais de 60 resumos científicos
BeOne Medicines is leading the oncology sector at ASCO and EHA 2026 with over 60 scientific abstracts. The company's presence at these major conferences highlights its commitment to advancing cancer research. Details on the specific abstracts or findings were not provided in the article.
Read more →ONCBeOne Medicines lanza "One Save Changes Everything", una campaña mundial de concientización sobre el cáncer con la leyenda del fútbol Tim Howard
BeOne Medicines has launched a global awareness campaign titled 'One Save Changes Everything' featuring football legend Tim Howard. The campaign aims to raise awareness about cancer. Details about the campaign's specific initiatives or goals were not provided in the article.
Read more →ONCSamenvatting: BeOne Medicines lanceert One Save Changes Everything, een wereldwijde campange ten behoeve van bewustwording voor kankerzorg met voetballegende Tim Howard
BeOne Medicines has launched a global awareness campaign titled 'One Save Changes Everything' featuring football legend Tim Howard. The campaign aims to raise awareness for cancer care. Further details about the campaign's objectives or activities were not provided in the article.
Read more →ONCRiassunto: BeOne Medicines lancia One Save Changes Everything, una campagna globale di sensibilizzazione alle cure oncologiche con la leggenda del calcio Tim Howard
BeOne Medicines has launched a global awareness campaign titled 'One Save Changes Everything,' featuring soccer legend Tim Howard. The initiative aims to raise awareness about cancer care. Further details about the campaign's goals or specific activities were not provided.
Read more →ONCBeOne Medicines startet „One Save Changes Everything“, eine weltweite Aufklärungskampagne zur Krebsbehandlung mit Fußballlegende Tim Howard
BeOne Medicines has launched a global awareness campaign titled 'One Save Changes Everything' aimed at cancer treatment. The campaign features football legend Tim Howard as a spokesperson. The initiative seeks to raise awareness about cancer and its treatment options, although specific details about the campaign's strategies and goals are not provided.
Read more →ONCBeOne Medicines lance « One Save Changes Everything », une campagne mondiale de sensibilisation aux soins contre le cancer en collaboration avec la légende du football Tim Howard
BeOne Medicines has launched a global awareness campaign titled 'One Save Changes Everything' in collaboration with football legend Tim Howard. The campaign aims to raise awareness about cancer care. Further details about the campaign's objectives and activities are not provided in the article.
Read more →ONCBeOne Medicines與足壇傳奇守門員Tim Howard攜手，推出「一次撲救，改變一切」全球癌症照護宣傳活動
BeOne Medicines has launched a global campaign featuring Tim Howard to promote awareness of a specific cancer condition. The initiative aims to encourage individuals to take action and make changes regarding their health. Further details about the campaign's objectives and strategies were not provided in the article.
Read more →ONCA BeOne Medicines lança campanha global de conscientização sobre o tratamento do câncer "One Save Changes Everything" (Uma Defesa Muda Tudo), com a participação da lenda do futebol Tim Howard
BeOne Medicines has launched a global awareness campaign titled 'One Save Changes Everything' aimed at promoting cancer treatment. The campaign features football legend Tim Howard, which is expected to draw significant attention to the cause. This initiative highlights the importance of awareness in cancer treatment and support.
Read more →ONCBeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts
BeOne Medicines is actively participating in oncology conferences, showcasing over 60 abstracts at ASCO and EHA 2026. This significant presence highlights their commitment to advancing oncology research. Further details about the abstracts or specific findings were not provided.
Read more →ONCSamenvatting: BeOne Medicines bepaalt de toon in oncologie tijdens ASCO en EHA 2026 met meer dan 60 abstracts
BeOne Medicines has made a significant impact in oncology at ASCO and EHA 2026, presenting over 60 abstracts. This showcases the company's commitment to advancing cancer research and treatment. The event highlights the importance of collaboration and innovation in the field of oncology.
Read more →ONCRiassunto: BeOne Medicines protagonista all'ASCO e all'EHA 2026 con oltre 60 abstract
BeOne Medicines is set to feature prominently at both the ASCO and EHA 2026 events with over 60 abstracts. This participation highlights the company's commitment to advancing research in oncology. The focus on these major conferences indicates a strategic approach to showcase their findings and innovations in the field.
Read more →ONCBeOne Medicines携手足坛传奇门将Tim Howard，发起“一次扑救，改变一切”全球癌症诊疗宣传活动
The article mentions an event involving BeOne Medicines and Tim Howard, but lacks detailed information about the event or its implications. It appears to focus on a promotional activity related to a global cancer diagnosis initiative. However, the content is insufficient for a comprehensive understanding.
Read more →ONCBeOne Medicines Launches One Save Changes Everything, a Global Cancer Care Awareness Campaign with Soccer Legend Tim Howard
BeOne Medicines has launched the 'One Save Changes Everything' campaign to raise global awareness about cancer care. The initiative features soccer legend Tim Howard, aiming to leverage his influence to promote cancer care initiatives. This campaign is expected to enhance public understanding and support for cancer-related issues.
Read more →ONCLa FDA américaine a approuvé le BEQALZI™ (sonrotoclax) de BeOne Medicines, le premier et unique inhibiteur de BCL2 indiqué dans le traitement du lymphome à cellules du manteau récidivant ou réfractaire
The FDA has approved BEQALZI™ (sonrotoclax) from BeOne Medicines, marking it as the first and only BCL2 inhibitor indicated for the treatment of relapsed or refractory mantle cell lymphoma. This approval provides a new therapeutic option for patients facing this challenging condition. The introduction of BEQALZI™ is expected to enhance treatment outcomes in this patient population.
Read more →ONCBEQALZI™ (sonrotoclax) da BeOne Medicines é aprovado pelo FDA dos EUA como o primeiro e único inibidor de BCL2 para linfoma de células do manto recidivado/refratário
The FDA has approved BEQALZI™ (sonrotoclax) from BeOne Medicines as the first and only BCL2 inhibitor for patients with relapsed/refractory mantle cell lymphoma. This approval represents a significant advancement in treatment options for this patient population, offering hope for improved outcomes.
Read more →ONCBEQALZI™ (sonrotoclax) de BeOne Medicines, aprobado por la FDA como el primer y único inhibidor de BCL2 para el linfoma de células del manto recidivante/refractario
The FDA has approved BEQALZI™ (sonrotoclax) from BeOne Medicines as the first and only BCL2 inhibitor for patients with relapsed/refractory mantle cell lymphoma. This approval marks a significant milestone in treatment options for this challenging condition, providing hope for improved patient outcomes.
Read more →ONCRiassunto: BEQALZI™ (sonrotoclax) di BeOne Medicines approvato dall'FDA statunitense come primo e unico inibitore del BCL2 nel trattamento del linfoma a cellule mantellari R/R
The FDA has approved BEQALZI™ (sonrotoclax) from BeOne Medicines as the first and only BCL2 inhibitor for treating relapsed/refractory mantle cell lymphoma (MCL). This approval represents a significant milestone in providing new therapeutic options for patients suffering from this challenging condition.
Read more →ONCBEQALZI™ (Sonrotoclax) von BeOne Medicines von der US-amerikanischen FDA als erster und einziger BCL2-Inhibitor für R/R-Mantelzelllymphom zugelassen
The FDA has approved BEQALZI™ (Sonrotoclax) from BeOne Medicines as the first and only BCL2 inhibitor for relapsed/refractory mantle cell lymphoma. This approval represents a significant advancement in treatment options for patients suffering from this aggressive form of lymphoma. BeOne Medicines aims to improve patient outcomes with this innovative therapy.
Read more →ONCSamenvatting: BEQALZI™ (sonrotoclax) van BeOne Medicines goedgekeurd door Amerikaanse FDA als eerste en enige BCL2-remmer voor recidiverend/refractair mantelcellymfoom
The FDA has approved BEQALZI™ (sonrotoclax) from BeOne Medicines, marking it as the first and only BCL2 inhibitor for treating relapsed/refractory mantle cell lymphoma. This approval represents a significant advancement in treatment options for patients suffering from this challenging condition. The introduction of BEQALZI™ is expected to improve patient outcomes in this specific cancer type.
Read more →ONCBeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma
BeOne Medicines has received FDA accelerated approval for BEQALZI™ (sonrotoclax), marking it as the first BCL2 inhibitor for adult patients with relapsed or refractory mantle cell lymphoma (MCL). This approval comes after patients have undergone at least two lines of systemic therapy. The drug represents a significant advancement in treatment options for this patient population.
Read more →ONCBeOne Medicines gibt die Finanzergebnisse für das erste Quartal 2026 sowie aktuelle Geschäftsentwicklungen bekannt
BeOne Medicines has announced its financial results for the first quarter of 2026 along with updates on its current business developments. The announcement provides insights into the company's performance and strategic direction. However, specific details regarding financial figures or business initiatives were not disclosed in the article.
Read more →ONCBeOne Medicines annonce ses résultats financiers et fait le point sur ses activités pour le premier trimestre 2026
BeOne Medicines has announced its financial results and provided an update on its activities for the first quarter of 2026. However, specific details regarding the financial performance or operational highlights were not disclosed in the article. The announcement appears to be routine without significant developments.
Read more →ONCBeOne Medicines da a conocer los resultados financieros del primer trimestre de 2026 y las últimas novedades sobre su actividad
BeOne Medicines announced its financial results for Q1 2026, but the article provides minimal information. Key financial metrics and operational updates are not detailed, leaving readers with little insight into the company's performance or future plans.
Read more →ONCBeOne Medicines公布2026年第一季財務業績及業務最新進展
BeOne Medicines has announced its financial results for the first quarter of 2026. The report includes updates on the company's operational progress and financial performance. However, specific details regarding the developments or financial figures were not disclosed in the article.
Read more →ONCBeOne Medicines anuncia resultados financeiros do primeiro trimestre de 2026 e atualizações sobre os negócios
BeOne Medicines announced its financial results for the first quarter of 2026. However, the article lacks detailed insights into the financial performance or any significant business updates. The information presented is minimal and does not provide a comprehensive view of the company's current status.
Read more →ONCSamenvatting: BeOne Medicines kondigt financiële resultaten en bedrijfsupdates voor het eerste kwartaal van 2026 aan
BeOne Medicines has announced its financial results and corporate updates for the first quarter of 2026. The details of the financial performance and any significant developments were not disclosed in the article. The announcement is part of the company's regular reporting schedule.
Read more →ONCRiassunto: BeOne Medicines annuncia i risultati finanziari relativi al primo trimestre 2026 e gli aggiornamenti aziendali
BeOne Medicines has announced its financial results for the first quarter of 2026 along with updates on its business operations. The article provides insights into the company's performance and strategic direction. However, specific details regarding financial figures or business developments are not included.
Read more →ONC▲ +5.3%on this newsshared move
Reconciliation of GAAP Operating Income Guidance to Non-GAAP Operating Income Guidance for Full Year 2026 (Unaudited) GAAP operating income 750,000 - 850,000 Plus Adjustments to arrive at Non-GAAP 1 700,000 - 700,000 Non
BeOne Medicines Ltd. reported strong first-quarter financial results for 2026, highlighting a 35% increase in total global revenues to $1.5 billion. The performance was driven by BRUKINSA, which generated $1.1 billion in global sales, marking a 38% growth. The company also showcased a significant rise in earnings per share and improved net income compared to the previous year. BeOne continues to enhance its market positioning through a robust pipeline and product innovations, reflecting its strength in the oncology sector.
Read more →ONC▲ +5.3%on this newsshared move
BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates
BeOne Medicines reported robust financial results for Q1 2026, with total revenues of $1.5 billion, marking a 35% increase from the previous year. The company highlighted the success of its leading product, BRUKINSA, which generated $1.1 billion in sales. BeOne's pipeline continues to expand, with over 20 abstracts accepted for presentation at ASCO, reinforcing its position in the oncology sector. The company also provided an optimistic revenue guidance for the full year 2026.
Read more →ONCLa FDA américaine accorde une évaluation prioritaire au TEVIMBRA de BeOne Medicines dans le traitement de première intention de l’adénocarcinome gastro-œsophagien HER2+
BeOne Medicines announced that the FDA has granted priority review for their supplemental biologics license application (sBLA) for TEVIMBRA (tislelizumab) in combination with ZIIHERA (zanidatamab) and chemotherapy for first-line treatment of HER2-positive gastroesophageal adenocarcinoma. The FDA also designated the therapy as innovative, highlighting its potential to significantly improve patient outcomes. The application is based on promising results from the HERIZON-GEA-01 study, which demonstrated a median overall survival of 26.4 months.
Read more →ONCDie US-amerikanische FDA bewilligt die vorrangige Prüfung von TEVIMBRA von BeOne Medicines als Erstlinienbehandlung bei HER2+ GEA
BeOne Medicines has received priority review from the FDA for TEVIMBRA (Tislelizumab) combined with ZIIHERA (Zanidatamab) and chemotherapy for treating HER2-positive gastroesophageal adenocarcinoma. The application is supported by promising data from the HERIZON-GEA-01 Phase 3 study, which demonstrated significant survival benefits. The FDA also granted Breakthrough Therapy designation for the treatment regimen.
Read more →ONCSamenvatting: Amerikaanse FDA kent Priority Review toe aan BeOne Medicines’ TEVIMBRA in eerstelijns HER2+ GEA
BeOne Medicines announced that the FDA has granted Priority Review for its supplemental Biologics License Application for TEVIMBRA in combination with ZIIHERA and chemotherapy. This treatment is aimed at first-line therapy for non-resectable locally advanced or metastatic HER2-positive gastric adenocarcinoma. The decision highlights the potential of this combination therapy in improving patient outcomes.
Read more →ONCLa FDA de Estados Unidos otorga revisión prioritaria a TEVIMBRA de BeOne Medicines en primera línea para HER2+ GEA
BeOne Medicines announced that the FDA has granted priority review for TEVIMBRA in combination with ZIIHERA and chemotherapy for first-line treatment of HER2+ gastric adenocarcinoma. The decision is based on interim results from the Phase 3 HERIZON-GEA-01 trial, which showed a significant survival benefit. The company aims to work with regulatory authorities to expedite the treatment's availability.
Read more →ONC美國FDA授予BeOne Medicines的TEVIMBRA用於HER2陽性胃食管腺癌一線治療的優先審評資格
BeOne Medicines has received FDA approval for TEVIMBRA (tislelizumab) in combination with ZIIHERA (zanidatamab) for the treatment of HER2-positive gastric cancer. This approval is based on promising interim results from the HERIZON-GEA-01 trial, which showed significant improvements in overall survival and progression-free survival. The combination therapy aims to provide a new treatment option for patients with this challenging cancer type.
Read more →ONCRiassunto: L'FDA statunitense concede la revisione prioritaria a TEVIMBRA di BeOne Medicines nel trattamento di prima linea dell'adenocarcinoma gastroesofageo HER2 positivo
BeOne Medicines announced that the FDA has granted priority review for TEVIMBRA (tislelizumab) in combination with ZIIHERA (zanidatamab) and chemotherapy. This treatment targets first-line therapy for locally advanced or metastatic HER2 positive gastroesophageal adenocarcinoma. This marks a significant step forward in addressing this challenging cancer type.
Read more →ONCA FDA dos EUA concede revisão prioritária ao TEVIMBRA da BeOne Medicines para o tratamento de primeira linha do adenocarcinoma gastroesofágico HER2+
BeOne Medicines has received Priority Review from the FDA for TEVIMBRA (tislelizumab) in combination with ZIIHERA (zanidatamab) and chemotherapy for first-line treatment of HER2-positive gastroesophageal adenocarcinoma. The FDA also granted Breakthrough Therapy designation for the ZIIHERA regimen. The pivotal HERIZON-GEA-01 study demonstrated significant improvements in overall survival and progression-free survival.
Read more →ONCU.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA
BeOne Medicines Ltd. announced that the U.S. FDA has granted Priority Review for its supplemental Biologics License Application for TEVIMBRA in combination with ZIIHERA and chemotherapy. This treatment is aimed at patients with unresectable locally advanced or metastatic HER2-positive gastric and gastroesophageal junction cancers. The Priority Review designation highlights the potential significance of this therapy in addressing unmet medical needs.
Read more →ONCBeOne Medicines to Announce First Quarter 2026 Financial Results on May 6
BeOne Medicines Ltd. will announce its first quarter 2026 financial results on May 6, 2026, before market opening. Following the announcement, a live webcast will be hosted by management at 8:00 a.m. ET. The company emphasizes its commitment to developing accessible cancer treatments globally.
Read more →ONC▼ -8.5%on this news
BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership
BeOne Medicines reported strong financial results for Q4 and full year 2025, with product revenue reaching $5.3 billion, a 40% increase from the previous year. The company highlighted BRUKINSA's leadership in the BTK inhibitor market and its expanding global presence. Despite some impairment charges and tax expenses, the outlook for 2026 remains positive with projected revenue growth.
Read more →ONC▼ -8.5%on this newsshared move
Fourth Quarter Full Year 2025 2024 2025 2024 Free Cash Flow (Non-GAAP) Net cash provided by (used in) operating activities (GAAP) $ 417,347 $ 75,160 $ 1,127,580 $ (140,631) Less Purchases of property, plant and equipment
BeOne Medicines Ltd. announced significant financial growth for the fourth quarter and full year of 2025, highlighting total global revenues of $1.5 billion and $5.3 billion, reflecting increases of 33% and 40% respectively. The company's flagship product, BRUKINSA, generated $1.1 billion in Q4 and $3.9 billion for the year, marking growth rates of 38% and 49%. The forecast for fiscal year 2026 anticipates revenues between $6.2 billion and $6.4 billion, driven by a strong market presence and regulatory approvals.
Read more →ONCBeOne Medicines to Present at Upcoming Investor Conferences
BeOne Medicines Ltd. announced its participation in four upcoming investor conferences, where it will engage in fireside chats. The company focuses on developing innovative cancer treatments and has a diverse pipeline aimed at hematology and solid tumors. Live webcasts of the events will be available on their website, along with archived replays.
Read more →ONCBeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26
BeOne Medicines Ltd. will announce its fourth quarter and full year 2025 financial results on February 26, 2026, before market opening. Following the announcement, a live webcast will be held at 8:00 a.m. ET. BeOne is focused on developing innovative oncology treatments and has a significant global workforce.
Read more →ONCBeOne Medicines亮相第44屆J.P. Morgan醫療健康大會，彰顯全球腫瘤領域領導地位
BeOne Medicines presented at the 44th annual J.P. Morgan Healthcare Conference, highlighting its advancements in the global oncology sector. CEO John V. Oyler emphasized the company's focus on innovative therapies for chronic lymphocytic leukemia (CLL) and its strong market position. The presentation outlined BeOne's pipeline, including promising candidates like BRUKINSA and sonrotoclax, aimed at improving treatment outcomes for patients.
Read more →ONC▲ +5.1%on this newsshared move
BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference
BeOne Medicines is showcasing its leadership in oncology at the J.P. Morgan Healthcare Conference. The company highlights its innovative treatments for B-cell malignancies, including BRUKINSA, a leading BTK inhibitor. BeOne's strong financial position supports its growth and development of new therapies. The presentation emphasizes the potential of its investigational drugs and internal capabilities to address unmet patient needs.
Read more →ONCBeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference
BeOne Medicines Ltd. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. The presentation is scheduled for 7:30 am PST. The company focuses on developing innovative oncology treatments and aims to enhance accessibility for cancer patients worldwide. Archived webcasts will be available on their website.
Read more →ONCSonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies
BeOne Medicines presented promising data on sonrotoclax, a novel BCL2 inhibitor, at the ASH 2025 meeting. The drug demonstrated significant clinical benefits as both monotherapy and in combination, particularly in relapsed/refractory mantle cell lymphoma (MCL) and treatment-naive chronic lymphocytic leukemia (CLL). Sonrotoclax could potentially transform treatment outcomes for patients with B-cell malignancies.
Read more →ONCU.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
BeOne Medicines announced that the FDA has granted Priority Review for sonrotoclax, a BCL2 inhibitor, aimed at treating adult patients with relapsed or refractory mantle cell lymphoma. The application is supported by data from a Phase 1/2 study demonstrating significant efficacy and tolerability. The full results will be presented at the upcoming ASH Annual Meeting.
Read more →ONCThree Months Ended September 30, Nine Months Ended
BeOne Medicines reported strong financial results for the third quarter of 2025, with total revenues rising by 41% to $1.4 billion, primarily fueled by a 51% increase in BRUKINSA sales. The company's net income reached $125 million, a substantial turnaround from a loss in the prior year. BeOne also reported improvements in gross margins and reiterated its positive outlook for the full year with updated revenue guidance. The results highlight the company's strong position in the oncology market, driven by robust performance in both U.S. and European markets.
Read more →ONCThree Months Ended June 30, Six Months Ended
BeOne Medicines Ltd. reported its second quarter 2025 financial results, revealing a 42% revenue increase to $1.3 billion compared to the prior year. The company's leading product, BRUKINSA, saw a 49% revenue rise, achieving $950 million in sales. With anticipated progress in over 20 milestones across its pipeline in the near future, the company is poised for continued growth in the oncology sector. The updated full-year guidance also reflects positive revenue expectations based on its key market positions.
Read more →ONCReconciliation of GAAP to adjusted EPS - basic GAAP earnings (loss) per share - basic $ 0.00 $ (0.19) Plus Share-based compensation expenses 0.07 0.07 Plus Depreciation 0.02 0.02 Plus Amortization of intangibles 0.00 0.0
BeiGene, Ltd. has reported a strong performance in its first quarter of 2025, with total revenues increasing by 49% to $1.1 billion, primarily driven by robust sales of its drug BRUKINSA. The company has achieved GAAP profitability for the first time, showcasing improved financial health. In addition to financial results, BeiGene received shareholder approval to change its name to BeOne Medicines, Ltd. and plans to redomicile to Switzerland. The company also anticipates multiple proof-of-concept readouts for its late-stage pipelines throughout the year.
Read more →ONC▲ +7.5%on this news
RECONCILIATION OF SELECTED GAAP MEASURES TO NON-GAAP MEASURES (Amounts in thousands of U.S. Dollars) (unaudited) Fourth Quarter Full Year 2024 2023 2024 2023 Reconciliation of GAAP to adjusted cost of sales - products GA
BeiGene reported exceptional financial results for Q4 and the full year of 2024, showcasing a revenue increase of 78% and 55%, respectively. BRUKINSA revenues alone surged by 100%, affirming its strong market position. The company anticipates achieving positive GAAP operating income and cash flow generated from operations in 2025. Despite the growth, the company still recorded GAAP operating losses, and collaboration revenues faced a significant decline, highlighting areas of concern moving forward.
Read more →ONCRECONCILIATION OF SELECTED GAAP MEASURES TO NON-GAAP MEASURES (Amounts in thousands of U.S. Dollars) (unaudited) Three Months Ended Nine Months Ended September 30
BeiGene reported strong financial results for Q3 2024, with total revenues reaching $1 billion, a 28% increase year-over-year. The company highlighted the success of its primary product, BRUKINSA, which generated $690 million in global revenue and is leading in new patient starts for chronic lymphocytic leukemia. BeiGene's pipeline also saw the addition of four new molecular entities entering clinical trials, aligning with its objective to introduce over ten new candidates by year-end. Overall, the company continues to focus on enhancing its global oncology leadership and expanding its commercial capabilities.
Read more →ONCRECONCILIATION OF SELECTED GAAP MEASURES TO NON-GAAP MEASURES (in thousands, except per share amounts) (unaudited) Three Months Ended Six Months Ended June 30
BeiGene reported a strong Q2 2024, with total revenues reaching $929 million, up 56% year-over-year and a positive non-GAAP operating income. The company highlighted significant growth in BRUKINSA sales, particularly in the U.S. and Europe, driven by its increasing market share. However, the report also noted a dramatic decrease in revenue from collaborations and a deferral in FDA approval for tislelizumab due to clinical site inspection delays. BeiGene continues to advance its oncology pipeline with several promising candidates in development.
Read more →ONCRECONCILIATION OF SELECTED GAAP MEASURES TO NON-GAAP MEASURES (in thousands, except per share amounts) (unaudited) Three Months Ended
BeiGene reported strong first-quarter financial results for 2024, with total revenues reaching $752 million, an increase of 68% compared to the prior year. Product revenue for BRUKINSA grew significantly, particularly in the U.S. and Europe, following its recent FDA approval. The company is focusing on advancing its innovative therapies for hematologic malignancies and solid tumors, while also expecting to open a new biologics manufacturing facility in New Jersey. Despite these positives, the company faced a substantial drop in collaboration revenues and still operates at a GAAP loss.
Read more →ONCFinancial Information On
BeiGene, Ltd. filed its 2023 Annual Report with the STAR Market of the Shanghai Stock Exchange, complying with PRC Securities Laws. The report includes key financial metrics such as gross profit margins and R&D expenses, with notable figures showing growth in revenue from various regions. However, the report's accessibility is limited to Chinese, and the differences between PRC GAAP and U.S. GAAP may pose challenges for international financial analysis.
Read more →ONCBeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer Comprehensive development program, including three Phase 3 clinical trials, demonstrated benefit of tislelizumab
BeiGene has received European Commission approval for tislelizumab as a treatment for non-small cell lung cancer (NSCLC) across multiple indications. This marks the drug's second approval in Europe, following its recent authorization for esophageal squamous cell carcinoma. Derived from the RATIONALE program's successful Phase 3 trials, tislelizumab is designed to significantly improve patient outcomes with manageable safety profiles. The drug is set to launch under the brand name TIZVENI in various EU countries in 2024.
Read more →ONCBeiGene Receives FDA Approval for TEVIMBRA for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy Results from the global, Phase 3 RATIONALE 302 trial showed TEVIMBRA prol
BeiGene has received FDA approval for TEVIMBRA (tislelizumab-jsgr) as a monotherapy for treating advanced or metastatic esophageal squamous cell carcinoma after prior chemotherapy. Based on the positive results of the global Phase 3 RATIONALE 302 trial, TEVIMBRA showed a median overall survival benefit of 8.6 months compared to 6.3 months for chemotherapy. This approval marks the first U.S. indication for TEVIMBRA, with the drug expected to be available in the second half of 2024. The approval highlights BeiGene’s commitment to expanding treatment options for patients suffering from this aggressive cancer type.
Read more →ONCAbout BeiGene BeiGene is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a broad portfolio, we are expediting
BeiGene reported strong financial results for Q4 and full-year 2023, showcasing continued growth with total revenues reaching $634 million in Q4 and $2.5 billion for the year. The company marked a significant increase in sales of BRUKINSA, driving its leadership in hematology. BeiGene commenced multiple registrational trials for innovative therapies while expanding its product indications. Despite impressive sales growth, the company continues to experience notable operating losses amidst rising expenditures.
Read more →ONCAbout BeiGene BeiGene is a global biotechnology company that is discovering and developing innovative oncology treatments that are more affordable and accessible to cancer patients worldwide. With a broad portfolio, we a
BeiGene reported impressive financial results for the third quarter of 2023, with total revenue hitting $781 million, representing a 102% increase year-over-year. Significant growth was observed in product sales, particularly for BRUKINSA, which saw a 130% increase to $358 million. The company also secured EU approval for TEVIMBRA, enhancing its oncology product offerings. However, operating expenses rose by 9.3%, and cash reserves decreased from previous levels, presenting some challenges amidst strong revenue growth.
Read more →ONCAbout BeiGene BeiGene is a global biotechnology company that is developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for far more patients worldwide. With a
BeiGene reported notable financial results for Q4 and full year 2022, with product revenues reaching $339.0 million and $1.3 billion, marking significant year-over-year increases. The company's BRUKINSA and tislelizumab contributed to this growth, with BRUKINSA achieving FDA approval for treating CLL/SLL, further enhancing its market position. Despite these successes, BeiGene reported a net loss of $2.0 billion for the year, influenced partly by foreign exchange losses. The company continues to maintain a strong cash position, aiming for long-term growth fueled by its innovative therapies.
Read more →ONCBeiGene Receives European Commission Approval for BRUKINSA (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma BRUKINSA is the first and only Bruton's Tyrosine Kinase (BTK) inhibitor for marginal zone
BeiGene Receives European Commission Approval for BRUKINSA (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma BRUKINSA is the first and only Bruton's Tyrosine Kinase (BTK) inhibitor for marginal zone lymphoma approved in the European Union CAMBRIDGE, U.S., B
Read more →ONCBeiGene Announces Positive Topline Results from Final Progression-Free Survival Analysis of BRUKINSA (zanubrutinib) Compared to IMBRUVICA (ibrutinib) in Phase 3 Chronic Lymphocytic Leukemia (CLL) Trial CAMBRIDGE, Mass. B
BeiGene Announces Positive Topline Results from Final Progression-Free Survival Analysis of BRUKINSA (zanubrutinib) Compared to IMBRUVICA (ibrutinib) in Phase 3 Chronic Lymphocytic Leukemia (CLL) Trial CAMBRIDGE, Mass. BASEL, Switzerland BEIJING - October 12, 2022 - BeiGene (NAS
Read more →ONCBeiGene Receives Positive CHMP Opinion for BRUKINSA (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma CHMP recommends approval of BRUKINSA for the treatment of relapsed or refractory marginal zone ly
BeiGene Receives Positive CHMP Opinion for BRUKINSA (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma CHMP recommends approval of BRUKINSA for the treatment of relapsed or refractory marginal zone lymphoma If approved, BRUKINSA will be the first and only ap
Read more →ONCBeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral Presentation for Tislelizumab in First-Line Unresectable Hepatocellular Cancer Tislelizumab demonstrated non-inferiority for overall survival
BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral Presentation for Tislelizumab in First-Line Unresectable Hepatocellular Cancer Tislelizumab demonstrated non-inferiority for overall survival and favorable safety profile versus sorafenib in global Ph
Read more →ONCBeiGene Announces Acceptance of 11th Regulatory Submission for PD-1 Inhibitor Tislelizumab in China Submission seeks marketing authorization for first-line use in combination with chemotherapy in advanced esophageal squa
BeiGene Announces Acceptance of 11th Regulatory Submission for PD-1 Inhibitor Tislelizumab in China Submission seeks marketing authorization for first-line use in combination with chemotherapy in advanced esophageal squamous cell carcinoma CAMBRIDGE, U.S., BASEL, Switzerland BE
Read more →ONCBeiGene Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab in First-Line Unresectable Hepatocellular Cancer Trial met primary endpoint of non-inferior overall survival versus sorafenib Result
BeiGene Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab in First-Line Unresectable Hepatocellular Cancer Trial met primary endpoint of non-inferior overall survival versus sorafenib Results mark eighth positive Phase 3 trial readout for tislelizu
Read more →ONCBeiGene Provides Regulatory Update on the U.S. Biologics License Application (BLA) for PD-1 Inhibitor Tislelizumab in 2L ESCC FDA Defers Action on BLA Until Required Inspections Can Be Completed Due to COVID Travel Restr
BeiGene Provides Regulatory Update on the U.S. Biologics License Application (BLA) for PD-1 Inhibitor Tislelizumab in 2L ESCC FDA Defers Action on BLA Until Required Inspections Can Be Completed Due to COVID Travel Restrictions, Inspections Could Not Be Completed During Review
Read more →ONCBeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tislelizumab Plus Chemotherapy in First-Line Advanced or Metastatic Esophageal Squamous Cell Carcinoma PD-1 inhibitor tislelizumab plus
BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tislelizumab Plus Chemotherapy in First-Line Advanced or Metastatic Esophageal Squamous Cell Carcinoma PD-1 inhibitor tislelizumab plus chemotherapy demonstrated a statistically significant and
Read more →ONCBeiGene Announces Acceptance of Supplemental Biologics License Application in China for Anti-PD-1 Inhibitor Tislelizumab Submission seeks marketing authorization for use with chemotherapy as first-line treatment in patie
BeiGene Announces Acceptance of Supplemental Biologics License Application in China for Anti-PD-1 Inhibitor Tislelizumab Submission seeks marketing authorization for use with chemotherapy as first-line treatment in patients with advanced gastric or gastroesophageal junction aden
Read more →ONCBeiGene Highlights Growing Portfolio and Pipeline Targeting Hematologic Malignancies at European Hematology Association 2022 Congress Clinical data and patient-reported outcomes across extensive clinical development prog
BeiGene Highlights Growing Portfolio and Pipeline Targeting Hematologic Malignancies at European Hematology Association 2022 Congress Clinical data and patient-reported outcomes across extensive clinical development program for zanubrutinib (BRUKINSA ) reinforce its potential ac
Read more →ONCBeiGene Clinical Data Presentations at 2022 ASCO Annual Meeting Demonstrate Mature and Growing Oncology Portfolio Long-term follow-up data from the Phase 3 ASPEN head-to-head trial of zanubrutinib versus ibrutinib in Wal
BeiGene Clinical Data Presentations at 2022 ASCO Annual Meeting Demonstrate Mature and Growing Oncology Portfolio Long-term follow-up data from the Phase 3 ASPEN head-to-head trial of zanubrutinib versus ibrutinib in Waldenstr m macroglobulinemia Results from the Phase 2 ROSEWO
Read more →ONCAbout BeiGene BeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. With a broad portfolio of
BeiGene Reports First Quarter 2022 Financial Results Recorded product revenue of $261.6 million for the first quarter, representing a 146% increase from $106.1 million in the prior year period BRUKINSA product revenue increased 372% globally versus the first quarter of 2021, le
Read more →ONCChina NMPA Approves Tislelizumab for Patients with Second-Line Esophageal Squamous Cell Carcinoma Tislelizumab is now approved for eight indications in China CAMBRIDGE, Mass. BASEL, Switzerland BEIJING-- BeiGene, Ltd. (N
China NMPA Approves Tislelizumab for Patients with Second-Line Esophageal Squamous Cell Carcinoma Tislelizumab is now approved for eight indications in China CAMBRIDGE, Mass. BASEL, Switzerland BEIJING-- BeiGene, Ltd. (NASDAQ BGNE HKEX 06160 SSE 688235), a global, science-drive
Read more →ONCBeiGene Announces European Medicines Agency Acceptance of Marketing Authorization Applications for Tislelizumab for the Treatment of Patients with ESCC and NSCLC First European Submissions for BeiGene's Anti PD-1 antibod
BeiGene Announces European Medicines Agency Acceptance of Marketing Authorization Applications for Tislelizumab for the Treatment of Patients with ESCC and NSCLC First European Submissions for BeiGene's Anti PD-1 antibody Licensed to Novartis for North America, Europe and Japan
Read more →ONCChina NMPA Approves Tislelizumab for Patients with Microsatellite Instability-High or Mismatch Repair-Deficient Solid Tumors Tislelizumab is now approved in seven indications in China CAMBRIDGE, Mass., BEIJING, and BASEL
China NMPA Approves Tislelizumab for Patients with Microsatellite Instability-High or Mismatch Repair-Deficient Solid Tumors Tislelizumab is now approved in seven indications in China CAMBRIDGE, Mass., BEIJING, and BASEL - March 11, 2022 -- BeiGene, Ltd. (NASDAQ BGNE HKEX 06160
Read more →ONCBeiGene Announces European Medicines Agency Acceptance of Applications for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia and Marginal Zone Lymphoma The CLL filing is supported by two global Phase 3 trials of BR
BeiGene Announces European Medicines Agency Acceptance of Applications for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia and Marginal Zone Lymphoma The CLL filing is supported by two global Phase 3 trials of BRUKINSA in chronic lymphocytic leukemia covering both treatm
Read more →ONCDrs. Margaret Dugan and Alessandro Riva Appointed to BeiGene Board of Directors Industry Leaders Lend Scientific and Clinical Expertise to Several Board Committees CAMBRIDGE, Mass. and BEIJING
Drs. Margaret Dugan and Alessandro Riva Appointed to BeiGene Board of Directors Industry Leaders Lend Scientific and Clinical Expertise to Several Board Committees CAMBRIDGE, Mass. and BEIJING-February 1, 2022-BeiGene (NASDAQ BGNE HKEX 06160 SSE 688235), a global, science-drive
Read more →ONCBeiGene Announces Acceptance of a Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Waldenstr m's Macroglobulinemia BRUKINSA received the China NMPA approval for the treatment of patients with rel
BeiGene Announces Acceptance of a Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Waldenstr m's Macroglobulinemia BRUKINSA received the China NMPA approval for the treatment of patients with relapsed or refractory Waldenstr m's macroglobulinemia (WM)
Read more →ONCChina NMPA Approves Tislelizumab as Second- or Third-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Tislelizumab is now approved in six indications in China This marks tisleliz
China NMPA Approves Tislelizumab as Second- or Third-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Tislelizumab is now approved in six indications in China This marks tislelizumab's third approved lung cancer indication in China and
Read more →ONCBeiGene Expands Collaboration with Novartis to Develop and Commercialize BeiGene's TIGIT Inhibitor and Market Five Novartis Oncology Medicines in China Broad Markets Strategic collaboration expected to advance clinical d
BeiGene Expands Collaboration with Novartis to Develop and Commercialize BeiGene's TIGIT Inhibitor and Market Five Novartis Oncology Medicines in China Broad Markets Strategic collaboration expected to advance clinical development of ociperlimab in combination with tislelizumab,
Read more →ONCBeiGene Announces Closing of Its RMB22.2 Billion (US$3.5 Billion) Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China RMB Shares begin trading on the STAR Market under the stock code "68823
BeiGene Announces Closing of Its RMB22.2 Billion (US$3.5 Billion) Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China RMB Shares begin trading on the STAR Market under the stock code "688235", making BeiGene the first triple-listed biotech company
Read more →ONCBeiGene Presents Results from Phase 3 Trial of Tislelizumab in Nasopharyngeal Cancer at ESMO Immuno-Oncology Congress 2021 In RATIONALE 309, tislelizumab in combination with chemotherapy significantly prolonged progressi
BeiGene Presents Results from Phase 3 Trial of Tislelizumab in Nasopharyngeal Cancer at ESMO Immuno-Oncology Congress 2021 In RATIONALE 309, tislelizumab in combination with chemotherapy significantly prolonged progression-free survival for patients, with survival benefit observ
Read more →ONCBeiGene Announces Pricing of its RMB22.2 billion (US$3.5 billion) Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China CAMBRIDGE, Mass. BEIJING
BeiGene Announces Pricing of its RMB22.2 billion (US$3.5 billion) Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China CAMBRIDGE, Mass. BEIJING - November 3, 2021 - BeiGene, Ltd. (NASDAQ BGNE HKEX 06160), a global, science-driven biotechnology compa
Read more →ONCBeiGene Launches Proposed Initial Public Offering on the STAR Market in China Cambridge, Mass. and Beijing, China
BeiGene Launches Proposed Initial Public Offering on the STAR Market in China Cambridge, Mass. and Beijing, China, November 23, 2021 - BeiGene, Ltd. (NASDAQ BGNE HKEX 06160), a global, science-driven biotechnology company focused on developing innovative and affordable medicines
Read more →ONCFinancial Information BeiGene, Ltd. (the "Company") previously submitted a listing application for a proposed public offering of the Company's ordinary shares and initial listing of such shares on the Science and Technol
Financial Information BeiGene, Ltd. (the "Company") previously submitted a listing application for a proposed public offering of the Company's ordinary shares and initial listing of such shares on the Science and Technology Innovation Board (the "STAR Market") of the Shanghai St
Read more →ONCBeiGene and Nanolek Announce Approval in Russia for BRUKINSA (Zanubrutinib) for Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma This marks the first regulatory approval for BRUKINSA in Russia BRUKI
BeiGene and Nanolek Announce Approval in Russia for BRUKINSA (Zanubrutinib) for Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma This marks the first regulatory approval for BRUKINSA in Russia BRUKINSA is now approved for the treatment of MCL in ten countr
Read more →ONCBeiGene Announces First Regulatory Approval in Australia for BRUKINSA (Zanubrutinib) for Treatment of Patients with Waldenstr m's Macroglobulinemia Represents BRUKINSA's Second Recent Approval in the Asia-Pacific Region,
BeiGene Announces First Regulatory Approval in Australia for BRUKINSA (Zanubrutinib) for Treatment of Patients with Waldenstr m's Macroglobulinemia Represents BRUKINSA's Second Recent Approval in the Asia-Pacific Region, Following October 1 Approval in Singapore for Treatment of
Read more →ONCBeiGene Receives Positive CHMP Opinion for BRUKINSA (Zanubrutinib) for the Treatment of Adults with Waldenstr m's Macroglobulinemia BeiGene's European commercial team is preparing to launch BRUKINSA, the company's first
BeiGene Receives Positive CHMP Opinion for BRUKINSA (Zanubrutinib) for the Treatment of Adults with Waldenstr m's Macroglobulinemia BeiGene's European commercial team is preparing to launch BRUKINSA, the company's first medicine submitted for marketing authorization in the EU, u
Read more →ONCBeiGene Announces U.S. FDA Acceptance of Biologics License Application for Tislelizumab in Esophageal Squamous Cell Carcinoma This marks the first ex-China regulatory filing for tislelizumab, following approval in five i
BeiGene Announces U.S. FDA Acceptance of Biologics License Application for Tislelizumab in Esophageal Squamous Cell Carcinoma This marks the first ex-China regulatory filing for tislelizumab, following approval in five indications in China The accepted BLA, filed in collaborati
Read more →ONCU.S. FDA Grants BRUKINSA (Zanubrutinib) Approval in Waldenstr m's Macroglobulinemia This marks the second FDA approval for BRUKINSA and its third approval in Waldenstr m's macroglobulinemia globally The approval is based
U.S. FDA Grants BRUKINSA (Zanubrutinib) Approval in Waldenstr m's Macroglobulinemia This marks the second FDA approval for BRUKINSA and its third approval in Waldenstr m's macroglobulinemia globally The approval is based on Phase 3 ASPEN trial comparing BRUKINSA against ibrutin
Read more →ONCBeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Nasopharyngeal Cancer CAMBRIDGE, Mass.
BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Nasopharyngeal Cancer CAMBRIDGE, Mass. BEIJING, China - August 22, 2021 - BeiGene, Ltd. (NASDAQ BGNE HKEX 06160), a global biotechnology company focused on developing and co
Read more →ONCBeiGene and EUSA Pharma Announce China NMPA Approval of QARZIBA (Dinutuximab Beta) for Patients with High-Risk Neuroblastoma CAMBRIDGE, Mass., BEIJING, China, and
BeiGene and EUSA Pharma Announce China NMPA Approval of QARZIBA (Dinutuximab Beta) for Patients with High-Risk Neuroblastoma CAMBRIDGE, Mass., BEIJING, China, and HEMEL HEMPSTEAD, England - August 17, 2021 - BeiGene, Ltd. (NASDAQ BGNE HKEX 06160) and EUSA Pharma (UK), Ltd. today
Read more →ONCBeiGene Announces Approval in Canada of BRUKINSA (Zanubrutinib) for the Treatment of Patients with Mantle Cell Lymphoma Second approval for BTK Inhibitor BRUKINSA in Canada CAMBRIDGE, Mass. and
BeiGene Announces Approval in Canada of BRUKINSA (Zanubrutinib) for the Treatment of Patients with Mantle Cell Lymphoma Second approval for BTK Inhibitor BRUKINSA in Canada CAMBRIDGE, Mass. and BEIJING, China, July 26, 2021 -- BeiGene, Ltd. (NASDAQ BGNE HKEX 06160), a global, s
Read more →ONCBeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC) CAMBRIDGE, Mass and
BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC) CAMBRIDGE, Mass and BEIJING, China, July 7, 2021 -- BeiGene, Ltd. (NASDAQ BGNE HKEX 06160), a global biotechnology company focused
Read more →ONCFinancial Information BeiGene, Ltd. (the "Company") previously submitted a listing application (as updated from time to time, the "Listing Application") for a proposed public offering of the Company's ordinary shares and
Financial Information BeiGene, Ltd. (the "Company") previously submitted a listing application (as updated from time to time, the "Listing Application") for a proposed public offering of the Company's ordinary shares and initial listing of such shares on the Science and Technolo
Read more →ONCChina NMPA Approves Tislelizumab in Non-Small Cell Lung Cancer and Hepatocellular Carcinoma Tislelizumab is approved for the first-line treatment of advanced non-squamous non-small cell lung cancer following the previous
China NMPA Approves Tislelizumab in Non-Small Cell Lung Cancer and Hepatocellular Carcinoma Tislelizumab is approved for the first-line treatment of advanced non-squamous non-small cell lung cancer following the previously approved squamous histology Tislelizumab receives its f
Read more →ONCBeiGene Announces China NMPA Approval of BRUKINSA (Zanubrutinib) for the Treatment of Patients with Relapsed or Refractory Waldenstr m's Macroglobulinemia Third approval for BRUKINSA in China and second approval in WM wo
BeiGene Announces China NMPA Approval of BRUKINSA (Zanubrutinib) for the Treatment of Patients with Relapsed or Refractory Waldenstr m's Macroglobulinemia Third approval for BRUKINSA in China and second approval in WM worldwide CAMBRIDGE, Mass. and BEIJING, China, June 18, 2021
Read more →ONCBeiGene Announces First Patient Dosed in Global Phase 3 Trial of Anti-TIGIT Antibody Ociperlimab in Non-Small Cell Lung Cancer CAMBRIDGE, Mass. and
BeiGene Announces First Patient Dosed in Global Phase 3 Trial of Anti-TIGIT Antibody Ociperlimab in Non-Small Cell Lung Cancer CAMBRIDGE, Mass. and BEIJING, China - June 17, 2021 -- BeiGene, Ltd. (NASDAQ BGNE HKEX 06160), a global biotechnology company focused on developing and
Read more →ONCShoreline Biosciences and BeiGene Announce Strategic Worldwide Collaboration to Develop and Commercialize Genetically Modified Natural Killer (NK) Cell Therapies BeiGene has worldwide development and commercialization ri
Shoreline Biosciences and BeiGene Announce Strategic Worldwide Collaboration to Develop and Commercialize Genetically Modified Natural Killer (NK) Cell Therapies BeiGene has worldwide development and commercialization rights, with Shoreline having an option to retain U.S. and Ca
Read more →ONCBeiGene Presents Clinical Data from Two Pivotal Trials of Tislelizumab at the 2021 ASCO Annual Meeting Compared to chemotherapy, tislelizumab demonstrated a statistically significant and clinically meaningful improvement
BeiGene Presents Clinical Data from Two Pivotal Trials of Tislelizumab at the 2021 ASCO Annual Meeting Compared to chemotherapy, tislelizumab demonstrated a statistically significant and clinically meaningful improvement in overall survival in patients with previously treated, a
Read more →ONCBeiGene Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for BRUKINSA (Zanubrutinib) in Marginal Zone Lymphoma CAMBRIDGE, Mass.
BeiGene Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for BRUKINSA (Zanubrutinib) in Marginal Zone Lymphoma CAMBRIDGE, Mass. BEIJING, China - May 19, 2021 - BeiGene, Ltd. (NASDAQ BGNE HKEX 06160), a global biotechnology company focused on
Read more →ONCBeiGene, Ltd. (the "Company") previously submitted a listing application (the "Listing Application") for a proposed public offering of the Company's ordinary shares and initial listing of such shares on the Science and T
BeiGene, Ltd. (the "Company") previously submitted a listing application (the "Listing Application") for a proposed public offering of the Company's ordinary shares and initial listing of such shares on the Science and Technology Innovation Board (the "STAR Market") of the Shangh
Read more →ONCChina NMPA Approves PARP Inhibitor Pamiparib for Patients with Previously Treated Advanced Ovarian Cancer Pamiparib becomes the first PARP inhibitor approved in both platinum-sensitive and platinum-resistant relapsed ova
China NMPA Approves PARP Inhibitor Pamiparib for Patients with Previously Treated Advanced Ovarian Cancer Pamiparib becomes the first PARP inhibitor approved in both platinum-sensitive and platinum-resistant relapsed ovarian cancer in China This marks the first approval of pam
Read more →ONCBRUKINSA (Zanubrutinib) Demonstrates Superior Objective Response Rate by Investigator Assessment and Reduced Rates of Atrial Fibrillation or Flutter at Interim Analysis in Head-to-Head Trial Against Ibrutinib in Chronic
BRUKINSA (Zanubrutinib) Demonstrates Superior Objective Response Rate by Investigator Assessment and Reduced Rates of Atrial Fibrillation or Flutter at Interim Analysis in Head-to-Head Trial Against Ibrutinib in Chronic Lymphocytic Leukemia CAMBRIDGE, Mass. and BEIJING, CHINA
Read more →ONCBeiGene Presents Clinical Data on Sitravatinib in Combination with Tislelizumab at the AACR Annual Meeting 2021 The combination showed preliminary antitumor activity in patients with unresectable or metastatic melanoma r
BeiGene Presents Clinical Data on Sitravatinib in Combination with Tislelizumab at the AACR Annual Meeting 2021 The combination showed preliminary antitumor activity in patients with unresectable or metastatic melanoma refractory or resistant to PD-1 L1 inhibitors and platinum-r
Read more →ONCBeiGene Announces First Commercial Manufacturing Approval for Its State-of-the-Art Biologics Facility in Guangzhou, China Commercial supply of tislelizumab for China now expanded with wholly owned manufacturing site BEIJ
BeiGene Announces First Commercial Manufacturing Approval for Its State-of-the-Art Biologics Facility in Guangzhou, China Commercial supply of tislelizumab for China now expanded with wholly owned manufacturing site BEIJING, China and CAMBRIDGE, Mass., April 7, 2021 -- BeiGene
Read more →ONCBeiGene Announces New Chief Financial Officer, Julia Wang Current CFO and Chief Strategy Officer Howard Liang, Ph.D. to Retire from BeiGene in June CAMBRIDGE, Mass. and BEIJING, China
BeiGene Announces New Chief Financial Officer, Julia Wang Current CFO and Chief Strategy Officer Howard Liang, Ph.D. to Retire from BeiGene in June CAMBRIDGE, Mass. and BEIJING, China -- March 30, 2021 -- BeiGene, Ltd. (NASDAQ BGNE HKEX 06160), a global biotechnology company fo
Read more →ONCBeiGene Initiates Phase 1 Clinical Trial for HPK1 Inhibitor BGB-15025 CAMBRIDGE, Mass. BEIJING - (BUSINESS WIRE)
BeiGene Initiates Phase 1 Clinical Trial for HPK1 Inhibitor BGB-15025 CAMBRIDGE, Mass. BEIJING - (BUSINESS WIRE)-Mar. 10, 2021-- BeiGene, Ltd. (NASDAQ BGNE HKEX 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldw
Read more →ONCBeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Second- or Third-line Non-Small Cell Lung Cancer BEIJING, China and
BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Second- or Third-line Non-Small Cell Lung Cancer BEIJING, China and CAMBRIDGE, Mass. - March 5, 2021 -- BeiGene, Ltd. (NASDAQ BGNE HKEX 06160), a commercial-stage biotechnol
Read more →ONCHealth Canada Approves BRUKINSA (Zanubrutinib) for the Treatment of Waldenstr m's Macroglobulinemia Approval is based on the Phase 3 ASPEN trial of BRUKINSA compared to ibrutinib This marks the first regulatory approval
Health Canada Approves BRUKINSA (Zanubrutinib) for the Treatment of Waldenstr m's Macroglobulinemia Approval is based on the Phase 3 ASPEN trial of BRUKINSA compared to ibrutinib This marks the first regulatory approval for BRUKINSA in Waldenstr m's macroglobulinemia, and BeiGe
Read more →ONCBeiGene Announces Closing of Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab in North America, Europe and Japan CAMBRIDGE, Mass. and
BeiGene Announces Closing of Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab in North America, Europe and Japan CAMBRIDGE, Mass. and BEIJING, China, February 26, 2021 (BUSINESSWIRE) -- BeiGene, Ltd. (NASDAQ BGNE HKEX 06160), a commercial-
Read more →ONCAbout BeiGene BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients
BeiGene Reports Fourth Quarter and Full Year 2020 Financial Results CAMBRIDGE, Mass. and BEIJING, China, February 25, 2021 -- BeiGene, Ltd. (NASDAQ BGNE HKEX 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide
Read more →ONCBeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (Zanubrutinib) in Waldenstr m's Macroglobulinemia CAMBRIDGE, Mass. and
BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (Zanubrutinib) in Waldenstr m's Macroglobulinemia CAMBRIDGE, Mass. and BEIJING, China - February 17, 2021 -- BeiGene, Ltd. (NASDAQ BGNE HKEX 06160), a commercial-stage biotechnology company
Read more →ONCFinancial Information BeiGene, Ltd. (the "Company") submitted a listing application (the "Listing Application") for a proposed issue of the Company's ordinary shares and listing of such shares on the Science and Technolo
Financial Information BeiGene, Ltd. (the "Company") submitted a listing application (the "Listing Application") for a proposed issue of the Company's ordinary shares and listing of such shares on the Science and Technology Innovation Board (the "STAR Market") of the Shanghai S
Read more →ONCBeiGene Announces Positive Topline Results for Global Phase 3 Trial of Tislelizumab in Esophageal Squamous Cell Carcinoma Tislelizumab prolonged the survival of patients with advanced unresectable or metastatic ESCC who
BeiGene Announces Positive Topline Results for Global Phase 3 Trial of Tislelizumab in Esophageal Squamous Cell Carcinoma Tislelizumab prolonged the survival of patients with advanced unresectable or metastatic ESCC who received prior systemic treatment compared to chemotherapy
Read more →ONCEUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for SYLVANT (Siltuximab for Injection) in China HEMEL HEMPSTEAD, England, BEIJING, China, and
EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for SYLVANT (Siltuximab for Injection) in China HEMEL HEMPSTEAD, England, BEIJING, China, and CAMBRIDGE, Mass. January 25, 2021 - EUSA Pharma (UK) Limited and BeiGene, Ltd. (NASDAQ BGNE HKEX 06160) to
Read more →ONCChina National Medical Products Administration Approves Tislelizumab in Combination with Chemotherapy in First-Line Advanced Squamous Non-Small Cell Lung Cancer BEIJING, China and
China National Medical Products Administration Approves Tislelizumab in Combination with Chemotherapy in First-Line Advanced Squamous Non-Small Cell Lung Cancer BEIJING, China and CAMBRIDGE, Mass., January 13, 2021 -- BeiGene, Ltd. (NASDAQ BGNE HKEX 06160), a commercial-stage bi
Read more →ONCBeiGene Announces Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab Novartis to co-develop and commercialize tislelizumab in North America, Japan, EU, and six other European countri
BeiGene Announces Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab Novartis to co-develop and commercialize tislelizumab in North America, Japan, EU, and six other European countries BeiGene to receive $650 million upfront payment and is
Read more →ONCDisclosures Certain statements contained in this presentation and in the accompanying oral presentation, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking
BeiGene Corporate Presentation January 10, 2021 Exhibit 99.1 2 Disclosures Certain statements contained in this presentation and in the accompanying oral presentation, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-look
Read more →ONCBeiGene Announces Inclusion of Three Innovative Oncology Products in China National Reimbursement Drug List (NRDL) Internally-developed anti-PD-1 antibody tislelizumab and BTK inhibitor BRUKINSA (zanubrutinib) are includ
BeiGene Announces Inclusion of Three Innovative Oncology Products in China National Reimbursement Drug List (NRDL) Internally-developed anti-PD-1 antibody tislelizumab and BTK inhibitor BRUKINSA (zanubrutinib) are included in the NRDL in a total of four approved indications XGE
Read more →ONCBeiGene Announces Data on BRUKINSA (Zanubrutinib) from Phase 2 Trial in Marginal Zone Lymphoma and Phase 3 Trial in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma at the 62 nd ASH Annual Meeting Zanubrutinib
BeiGene Announces Data on BRUKINSA (Zanubrutinib) from Phase 2 Trial in Marginal Zone Lymphoma and Phase 3 Trial in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma at the 62nd ASH Annual Meeting Zanubrutinib was shown to be highly active in patients with relapsed refr
Read more →ONCBeiGene Launches Proposed Public Offering by Selling Shareholders Cambridge, Mass. and Beijing, China
BeiGene Launches Proposed Public Offering by Selling Shareholders Cambridge, Mass. and Beijing, China, December 1, 2020 - BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwi
Read more →ONCDocument BeiGene Announces the Approval of XGEVA (Denosumab) in China for the Prevention of Skeletal-Related Events in Patients with Bone Metastases from Solid Tumors and in Patients with Multiple Myeloma BEIJING, China
BeiGene Announces the Approval of XGEVA (Denosumab) in China for the Prevention of Skeletal-Related Events in Patients with Bone Metastases from Solid Tumors and in Patients with Multiple Myeloma BEIJING, China and CAMBRIDGE, Mass., November 19, 2020 -- BeiGene, Ltd. (NASDAQ BGN
Read more →ONCDocument BeiGene Announces that RATIONALE 303 Trial of Tislelizumab in Non-Small Cell Lung Cancer Met the Primary Endpoint of Overall Survival at Interim Analysis RATIONALE 303 is a global Phase 3 trial of BeiGene's anti
BeiGene Announces that RATIONALE 303 Trial of Tislelizumab in Non-Small Cell Lung Cancer Met the Primary Endpoint of Overall Survival at Interim Analysis RATIONALE 303 is a global Phase 3 trial of BeiGene's anti-PD-1 antibody tislelizumab compared to docetaxel in the second- or
Read more →ONCDocument EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for QARZIBA (Dinutuximab Beta) in China HEMEL HEMPSTEAD, England, BEIJING, China, and
EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for QARZIBA (Dinutuximab Beta) in China HEMEL HEMPSTEAD, England, BEIJING, China, and CAMBRIDGE, Mass. November 9, 2020 - EUSA Pharma (UK) Limited and BeiGene, Ltd. (NASDAQ BGNE HKEX 06160) today ann
Read more →ONCBIOATLA AND BEIGENE REVISE GLOBAL DEVELOPMENT AND COMMERCIALIZATION AGREEMENT FOR NOVEL CONDITIONALLY ACTIVE BIOLOGIC CTLA-4 CANDIDATE BA3071 San Diego, CA Beijing, China and Cambridge, MA
BIOATLA AND BEIGENE REVISE GLOBAL DEVELOPMENT AND COMMERCIALIZATION AGREEMENT FOR NOVEL CONDITIONALLY ACTIVE BIOLOGIC CTLA-4 CANDIDATE BA3071 San Diego, CA Beijing, China and Cambridge, MA - October 6, 2020 - BioAtla, Inc., a global clinical-stage biotechnology company focused o
Read more →ONCBeiGene Announces Acceptance and Priority Review by Health Canada of New Drug Submission for BRUKINSA (zanubrutinib) in Waldenstr m's Macroglobulinemia CAMBRIDGE, Mass, and
BeiGene Announces Acceptance and Priority Review by Health Canada of New Drug Submission for BRUKINSA (zanubrutinib) in Waldenstr m's Macroglobulinemia CAMBRIDGE, Mass, and BEIJING, China, Sept. 9, 2020 - BeiGene, Ltd. (NASDAQ BGNE HKEX 06160), a commercial-stage biotechnology c
Read more →ONCBeiGene Appoints Corsee Sanders, Ph.D. to its Board of Directors CAMBRIDGE, Mass. and
BeiGene Appoints Corsee Sanders, Ph.D. to its Board of Directors CAMBRIDGE, Mass. and BEIJING, China, August 25, 2020 -- BeiGene, Ltd. (NASDAQ BGNE HKEX 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, tod
Read more →ONCBeiGene Announces Pricing of Approximately $2.08 Billion Registered Direct Offering CAMBRIDGE, Mass. and
BeiGene Announces Pricing of Approximately $2.08 Billion Registered Direct Offering CAMBRIDGE, Mass. and BEIJING, China, July 12, 2020 - BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative mo
Read more →ONCBeiGene Begins Commercializing XGEVA (Denosumab) in China BEIJING, China and
BeiGene Begins Commercializing XGEVA (Denosumab) in China BEIJING, China and CAMBRIDGE, Mass., June 30, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-t
Read more →ONCBeiGene Announces European Medicines Agency Acceptance of its Marketing Authorization Application for BRUKINSA (Zanubrutinib) for the Treatment of Patients with Waldenstr m's Macroglobulinemia CAMBRIDGE, Mass. and
BeiGene Announces European Medicines Agency Acceptance of its Marketing Authorization Application for BRUKINSA (Zanubrutinib) for the Treatment of Patients with Waldenstr m's Macroglobulinemia CAMBRIDGE, Mass. and BEIJING, China, June 18, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd.
Read more →ONCChina National Medical Products Administration Approves BeiGene's Tislelizumab for Patients with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
China National Medical Products Administration Approves BeiGene's Tislelizumab for Patients with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma BEIJING, China and CAMBRIDGE, Mass., April 10, 2020 (GLOBE NEWSWIRE) --BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160
Read more →ONCBeiGene Announces Supply Update for ABRAXANE in China
BeiGene Announces Supply Update for ABRAXANE in China BEIJING, China, and CAMBRIDGE, Mass., March 25, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly
Read more →ONCAbout BeiGene BeiGene is a global, commercial-stage research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 3,500 employees in the United States,
BeiGene Reports Fourth Quarter and Full Year 2019 Financial Results CAMBRIDGE, Mass. and BEIJING, China, March 2, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative
Read more →ONCBeiGene Reports Third Quarter 2019 Financial Results
BeiGene Reports Third Quarter 2019 Financial Results CAMBRIDGE, Mass. and BEIJING, China, November 12, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularl
Read more →ONCAbout BeiGene BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 2,700 employees in China, the United
BeiGene Reports Second Quarter 2019 Financial Results CAMBRIDGE, Mass. and BEIJING, China, August 8, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-
Read more →ONCBeiGene Regains Full Global Rights to Its Investigational Anti-PD-1 Antibody Tislelizumab CAMBRIDGE, Mass. and BEIJING, China
BeiGene Regains Full Global Rights to Its Investigational Anti-PD-1 Antibody Tislelizumab CAMBRIDGE, Mass. and BEIJING, China; June 17, 2019 (GLOBE NEWSWIRE) BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commerc
Read more →ONCAbout BeiGene BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of approximately 2,400 employees in China, th
BeiGene Reports First Quarter 2019 Financial Results CAMBRIDGE, Mass. and BEIJING, China, May 9, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targ
Read more →ONCAbout BeiGene BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 2,200 employees in China, the United
BeiGene Reports Fourth Quarter and Full Year 2018 Financial Results Company to Host Annual Results Conference Call Today at 6:00 p.m. EST and Investor Event in Hong Kong on February 28th at 2:30 p.m. HKT CAMBRIDGE, Mass. and BEIJING, China, February 27, 2019 (GLOBE NEWSWIRE) --
Read more →ONCCorporate Presentation January 6, 2019
Corporate Presentation January 6, 2019 2 Disclosures Certain statements contained in this presentation and in the accompanying oral presentation, other than statements of fact that are independently verifiable at the date hereof, may constitute forward - looking statements . Exa
Read more →ONCBeiGene Announces Acceptance of New Drug Application for Anti-PD-1 Antibody Tislelizumab in Hodgkin s Lymphoma in China BEIJING, China, and
BeiGene Announces Acceptance of New Drug Application for Anti-PD-1 Antibody Tislelizumab in Hodgkin s Lymphoma in China BEIJING, China, and CAMBRIDGE, Mass., August 31, 2018 (GLOBE NEWSWIRE) BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company
Read more →ONCBeiGene, Ltd . BeiGene Initiates New Phase 3 Trial of Anti-PD-1 Antibody Tislelizumab Combined with Chemotherapy as First-line Treatment for Patients with Advanced Squamous Non-Small Cell Lung Cancer in China BEIJING, Ch
BeiGene Initiates New Phase 3 Trial of Anti-PD-1 Antibody Tislelizumab Combined with Chemotherapy as First-line Treatment for Patients with Advanced Squamous Non-Small Cell Lung Cancer in China BEIJING, China, and CAMBRIDGE, Mass., Aug. 9, 2018 (GLOBE NEWSWIRE) BeiGene, Ltd. (NA
Read more →ONCBeiGene, Ltd . BeiGene Announces Pricing of Its HK$7.08 billion (US$903 million) Hong Kong Initial Public Offering and Global Offering BEIJING, China and
BeiGene Announces Pricing of Its HK$7.08 billion (US$903 million) Hong Kong Initial Public Offering and Global Offering BEIJING, China and CAMBRIDGE, Mass., Aug. 02, 2018 (GLOBE NEWSWIRE) BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on devel
Read more →ONCBeiGene, Ltd . BeiGene Announces Proposed Hong Kong Initial Public Offering and Global Offering CAMBRIDGE, Mass. and
BeiGene Announces Proposed Hong Kong Initial Public Offering and Global Offering CAMBRIDGE, Mass. and BEIJING, China, July 27, 2018 (GLOBE NEWSWIRE) BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative mol
Read more →ONCBeiGene, Ltd . BeiGene Announces Plan to Pursue Accelerated Approval in the U.S. of BTK Inhibitor Zanubrutinib in Waldenstr m Macroglobulinemia (WM) Fast Track Designation Granted by U.S. FDA Enrollment Complete in Globa
BeiGene Announces Plan to Pursue Accelerated Approval in the U.S. of BTK Inhibitor Zanubrutinib in Waldenstr m Macroglobulinemia (WM) Fast Track Designation Granted by U.S. FDA Enrollment Complete in Global Phase 3 Clinical Trial in WM CAMBRIDGE, Mass. and BEIJING, China, July
Read more →ONCBUSINESS Overview We are a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Our internally-developed
BUSINESS Overview We are a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Our internally-developed lead drug candidates are currently in late-stage clinical tr
Read more →Competitive Position
How ONC ranks across every disease it competes inCompetitive Position is a premium feature
See how ONC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial